NIAGARA: Impact of pCR on Long-Term Outcomes

At the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium, Matthew Galsky, MD, of Icahn School of Medicine at Mount Sinai, highlights the latest findings on the impact of pCR on long-term outcomes in the NIAGARA trial.

He also considers the additional follow-up analyses planned for NIAGARA, and what approach might be available to tease out the benefit of the neoadjuvant combination in this patient population.